TVRD at a glance
Tvardi Therapeutics, Inc. (TVRD, SEC CIK 1346830) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as June 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2024 (FY2024), Tvardi Therapeutics, Inc. (TVRD) reported revenue of $7.1 million (down 66.0% from FY2023) and a net loss of $70.9 million. Diluted EPS was -$15.53.
- As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding Tvardi Therapeutics, Inc. (TVRD) shares worth $2.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2024
- $7.1M
- −66.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 16 funds
- $2.0M · +3 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes identified from the March 31, 2026 Form 10-K
- Clinical-stage business risk: adverse events could impair financial condition, results, and growth prospects
- Market risk: adverse developments could reduce the common stock price
- Disclosure risk: unknown or currently immaterial risks could impair operations and stock value
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved or commercialized
- Net loss $6.1M vs $5.5M YoY, operating expenses $6.3M vs $5.9M
- Best program TTI-101 HCC spending $2.4M, up 307.0% YoY; TTI-109 spending $1.0M, down 49.0%
- Cash $22.3M at September 30, 2026; operating cash use $21.5M for nine months
- ATM proceeds $13.3M; substantial doubt about funding operations for at least one year, additional capital required
AI summary of the TVRD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- TTI-109 advanced toward an Investigational New Drug filing for inflammatory bowel disease
- FDA pre-IND feedback supports continued development of Tvardi’s next-generation oral STAT3 inhibitor
Item EX-99.1: Item EX-99.1
- FDA pre-IND feedback supports Phase 2 development approach for TTI-109 in ulcerative colitis and Crohn’s disease
- IND submission planned for 2027, with Phase 2 initiation contingent on FDA clearance and additional funding
Item EX-99.1: Item EX-99.1
- Q3 net loss $6.1M, or $(0.48) per share, versus $5.5M and $(0.59) year over year
- R&D expense $4.5M, up from $3.6M, reflecting higher TTI-101 clinical costs
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter results for period ended September 30, 2026 announced on November 13, 2026
- Business highlights included alongside quarterly financial results
Item EX-99.1: Item EX-99.1
- TTI-109 healthy-volunteer data confirmed TTI-101-equivalent exposure, improved tolerability, and reductions in UC-relevant immune populations
- UC selected as lead indication; U.S. addressable market approximately $3B versus $9B globally
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 results and business highlights announced August 14, 2026
- Financial details and operating updates contained in Exhibit 99.1 press release
AI summaries of TVRD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TVRD
Don't miss the next TVRD filing
- Alerts as it files. A push when TVRD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TVRD, by share count.
- Ask anything. An AI agent that reads every TVRD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HALL WALLACE L JR | A | Jun 9, 2026 | 6,000 | - |
| Shah Sujal | A | Jun 9, 2026 | 6,000 | - |
| Smith Cynthia | A | Jun 9, 2026 | 6,000 | - |
| WYZGA MICHAEL S | A | Jun 9, 2026 | 6,000 | - |
| Shiff Susan Ph.D. | A | Jun 9, 2026 | 6,000 | - |
| Alibhai Imran Nizamudin | A | Jan 29, 2026 | 115,000 | - |
| Conn Avi Daniel | A | Jan 29, 2026 | 45,000 | - |
| Kauh John Saewook M.D. | A | Jan 29, 2026 | 45,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $21.0M | $7.1M | - |
| Operating Income | -$121.5M | -$58.4M | -$26.7M |
| Net Income | - | -$70.9M | -$18.2M |
| Op. Margin | -579.4% | -818.0% | - |
| Net Margin | - | -993.0% | - |
| Balance Sheet | |||
| Total Assets | $125.8M | $43.8M | $32.1M |
| Equity | - | -$4.6M | $20.9M |
| ROE | - | 1542.9% | -87.0% |
| Per Share | |||
| EPS | $-2.19 | $-15.53 | $-3.26 |
| Cash Flow | |||
| Operating CF | -$92.1M | -$60.9M | -$23.5M |
| CapEx | $2.4M | $1.0M | - |
Source: XBRL data in Tvardi Therapeutics, Inc. (TVRD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TVRD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 16 | $2.0M |
| Q2 2026 | 13 | $1.3M |
| Q1 2026 | 16 | $3.7M |
| Q4 2025 | 16 | $5.6M |
| Q3 2025 | 15 | $43.2M |
| Q2 2025 | 12 | $18.6M |
- JPMorgan Chase & Co+202.3K (+160593%)
- Renaissance Technologies LLC+42.7K (+47%)
- Morgan Stanley+1.1K (+1%)
- Citigroup+9 (+900%)
- PNC Financial Services−3.5K (-100%)
- Wells Fargo & Co−1.3K (-99%)
- BlackRock−181 (-0%)
- Northern Trust−8 (-0%)
- Raymond James Financial+278.6K
- Two Sigma Investments+241.2K
- Bank of America Corp+132.2K
- Goldman Sachs Group+11.0K
- U.S. Bancorp+1.0K
- AQR Capital Management−27.1K
- FMR LLC (Fidelity)−1.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 88 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TVRD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 10-Q | Nov 13, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 10-Q | May 8, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 8, 2026 | - | Analysis | |
| 10-K | Mar 31, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 31, 2026 | - | - | - |
| 8-K | Mar 6, 2026 | - | Analysis | - |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 8-K | Jan 16, 2026 | - | - | |
| 4 | Dec 18, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TVRD SEC filings: frequently asked questions
Which institutions hold TVRD stock?
As of September 30, 2026, the largest Tvardi Therapeutics, Inc. (TVRD) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($430,000), Raymond James Financial ($348,000), Two Sigma Investments ($302,000), JPMorgan Chase & Co ($259,000), Renaissance Technologies LLC ($168,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TVRD's revenue in fiscal year 2024?
For the fiscal year ended December 31, 2024 (FY2024), Tvardi Therapeutics, Inc. (TVRD) reported revenue of $7.1 million (down 66.0% from FY2023) and a net loss of $70.9 million. Diluted EPS was -$15.53. The figures come from the XBRL data in the 10-K.
What did TVRD report in its latest 8-K?
Tvardi Therapeutics, Inc. (TVRD) filed an 8-K on November 19, 2026 reporting Item 7.01 (Regulation FD Disclosure). TTI-109 advanced toward an Investigational New Drug filing for inflammatory bowel disease.
What are the latest TVRD SEC filings?
Tvardi Therapeutics, Inc. (TVRD) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on June 11, 2026.
What is TVRD's SEC CIK number?
Tvardi Therapeutics, Inc. (TVRD)'s SEC Central Index Key (CIK) is 1346830. EDGAR lists every TVRD filing under that number.
Ask anything about TVRD
The research agent reads TVRD's filings, financials, insider trades and 13F holders, then answers with sources.